

## QleanAir wins an order for a cleanroom project within cell research at a large US health system

QleanAir AB (publ), the premium provider of solutions for clean indoor air, announces receiving an order worth 630,000 USD from a major university health and research organization to provide a cleanroom for research within cell and gene therapy.

The order is a result of a previously announced letter of intent from a major university health and research organization. The GMP classified cleanroom will be used for research and production within cell and gene therapy. Construction for the cleanroom will begin late Q1 and will end within Q2.

- "QleanAir is carefully and diligently working its way into markets new to the US business. This is one more step towards broadening our scope in providing high quality clean spaces in the US. It's especially exciting to do so with such a high profile and prestigious client", says Zachary Douglas, President of OleanAir Scandinavia Inc.

## For more information, please contact:

Christina Lindstedt, CEO
E-mail christina.lindstedt@qleanair.com
Cell +46 70 677 28 77

## About QleanAir

QleanAir is a niche premium provider of clean indoor environment solutions. The company's business model is based on lease contracts for modular solutions with a full-service offer. QleanAir solutions are developed using filter technology that traps, filters and recycles indoor air. The company has over 11,000 installed units at more than 3,000 customers on the markets for EMEA, APAC and the Americas. For full year 2021, net sales amounted to 450 MSEK and adjusted operating margin was 18.5 percent. QleanAir's head office is in Solna in Sweden, and the share is traded on Nasdaq First North Premier Growth Market, ticker QAIR. FNCA Sweden is Certified Adviser +46 8 528 00 399. For more information go to gleanair.com.

## **Attachments**

QleanAir wins an order for a cleanroom project within cell research at a large US health system